醫學新知
Update
無標題文件


首頁 > 醫學新知 > 醫學新知
Breaking news – new statement endorsed by the IMS reviews the ‘Management of aromatase inhibitor-associated bone loss in postmenopausal women with hormone-sensitive breast cancer’
2017-05-04

A new position paper has been published online in the Journal of Bone Oncology and endorsed by the IMS and other International Societies including IOF, CABS, ECTS, ESCEO, IEG, and SIGO JBO. This provides an updated algorithm better to assess fracture risk and direct treatment in the management of aromatase inhibitor-associated bone loss (AIBL). Mary Ann Lumsden, President of the IMS, comments: “Decreased bone density and fracture are a major issue for women taking aromatase inhibitors for treatment of breast cancer. Risk of fracture increases substantially and this will only get worse as the women age. This document highlights the importance of bone loss and suggests practical measures for treatment that are endorsed by several societies interested in diseases of bone from around the world. Hopefully, this means that, in the future, this problem will not be neglected and women will be monitored for bone loss and receive appropriate treatment at the right time.”

The Journal of Bone Oncology is an open-access journal which makes the paper easily availablev– just follow the link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384888



瀏覽次數: 678

Untitled Document